The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.

Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.

Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.

Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.

The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.

Microbiome startup AOBiome Therapeutics has seen positive data from its phase 2b trial in acne.

People are turning down jobs at AstraZeneca because of uncertainty about their right to stay in the United Kingdom after Brexit.

The mid-development tweaks have the blessing of regulators, enabling uniQure to start a pivotal trial next year with its fast-track statuses intact. 

Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.

OptiScan Biomedical scored an FDA nod for its bedside device that continuously monitors ICU patients’ glucose levels.